Immuneering Corp IMRX
We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. We are developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which we believe have the potential to be more effective and better tolerated targeted therapies.
Deep Cyclic Inhibition® ("DCI") is a novel mechanism that aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while sparing healthy cells through a cadenced, normalized level of signaling. Our Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the mitogen-activated protein kinase ("MAPK") pathway. Our novel approach is designed to improve durability and tolerability, and differentiates us from chronically targeted precision therapies, which are generally limited by toxicity, resistance and/or application to specific mutations only.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $317.0K | $2.1M | $2.3M | — |
| Cost of revenue | — | — | $0 | $158.1K | $1.2M | $1.3M | — |
| Gross profit | — | — | $0 | $158.8K | $926.9K | $1.0M | — |
| R&D | $42.0M | $48.0M | $41.6M | $36.3M | $26.5M | $15.0M | — |
| SG&A | $17.3M | $16.1M | $16.8M | $15.6M | $8.3M | $3.1M | — |
| Total operating expenses | $59.4M | $64.1M | $58.4M | $51.9M | $34.8M | $18.1M | — |
| Operating income | -$59.4M | -$64.1M | -$58.4M | -$51.7M | -$33.9M | -$17.1M | — |
| Pre-tax income | -$56.0M | — | — | -$50.5M | -$33.8M | -$17.0M | — |
| Income tax | $0 | — | — | — | $307.5K | — | — |
| Net income | -$56.0M | -$61.0M | -$53.5M | -$50.5M | -$33.5M | -$17.0M | — |
| EPS, basic | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 | -3.44 | — |
| EPS, diluted | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 | -3.44 | — |
| Shares, diluted (wtd. avg.) | 44.0M | 30.0M | 28.4M | 26.4M | 13.6M | 5.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $128.6M | $36.1M | $59.4M | $72.6M | $74.9M | $37.1M | $13.8M |
| Short-term investments | — | $0 | $26.3M | $32.9M | $74.3M | — | — |
| Receivables | — | — | $0 | $12.4K | $246.0K | $500.1K | — |
| Total current assets | $176.2M | $39.6M | $89.1M | $108.7M | $152.3M | $37.7M | — |
| Property, plant and equipment | $938.5K | $1.1M | $1.4M | $1.4M | $807.2K | $64.4K | — |
| Goodwill | $6.7M | $6.7M | $6.7M | $6.7M | $6.7M | — | — |
| Other intangibles | $321.1K | $350.4K | $379.7K | $408.9K | $439.0K | — | — |
| Total assets | $232.0M | $52.7M | $102.6M | $122.4M | $166.7M | $38.4M | — |
| Accounts payable | $1.5M | $2.0M | $2.1M | $3.2M | $1.4M | $1.5M | — |
| Total current liabilities | $10.1M | $7.5M | $7.8M | $8.1M | $5.6M | $2.3M | — |
| Total liabilities | $13.5M | $11.3M | $12.0M | $12.5M | $10.7M | $2.8M | — |
| Retained earnings | -$280.3M | -$224.3M | -$163.3M | -$109.8M | -$59.3M | -$25.7M | — |
| Total equity | $218.5M | $41.4M | $90.6M | $109.9M | $156.0M | -$22.5M | -$6.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.3M | -$55.0M | -$49.0M | -$44.1M | -$30.9M | -$14.6M | — |
| Depreciation and amortisation | $324.5K | $355.8K | $322.8K | $247.2K | $45.5K | $24.3K | — |
| Stock-based compensation | $6.3M | $6.5M | $5.7M | $4.1M | $1.8M | $1.1M | — |
| Capital expenditure | $142.2K | $84.9K | $342.7K | $742.5K | $60.8K | $53.4K | — |
| Investing cash flow | -$88.7M | $26.4M | $7.3M | $41.8M | -$75.6M | -$53.4K | — |
| Financing cash flow | $226.6M | $5.3M | $28.4M | $19.0K | $144.3M | $38.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001790340-26-000042.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $2.3M | $2.1M | $317.0K | $0 | — | — |
| Gross profit | — | $1.0M | $926.9K | $158.8K | $0 | — | — |
| Net income | — | -$17.0M | -$33.5M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |